Intellia's Latest Data Indicate Full Potential of CRISPR

Intellia Therapeutics reported early, positive signs from its in vivo gene therapies for both transthyretin (ATTR) amyloidosis and hereditary angioedema Friday.

The data released from the two early-stage programs represent a major milestone for each disease space and validate the company’s in-vivo-based CRISPR platform, John Leonard, Intellia’s chief executive, said in a conference call.